FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379508729> ?p ?o ?g. }

• W4379508729 endingPage "569" @default.
• W4379508729 startingPage "560" @default.
• W4379508729 abstract "Objectives: Anti-calcitonin gene-related peptide (CGRP) agents are some of the newest preventive medications for migraine. There is limited literature comparing the efficacy of the most recent CGRP antagonist, atogepant, to CGRP monoclonal antibodies for migraine prevention. In this network meta-analysis, the efficacy and safety of migraine treatments including different doses of atogepant and CGRP monoclonal antibodies were evaluated to provide a reference for future clinical trials. Materials and Methods: A search using PubMed, Embase, and Cochrane Library identified all randomized controlled trials published through May 2022 and including patients diagnosed with episodic or chronic migraine and treated with erenumab, fremanezumab, eptinezumab, galcanezumab, atogepant, or placebo. The primary outcomes were the reduction of monthly migraine days, 50% response rate, and the number of adverse events (AEs). The Cochrane Collaboration tool was used to assess the risk of bias. Results: In this study, 24 articles were considered for analysis. Regarding efficacy, all interventions were superior to placebo with a statistically significant difference. The most effective intervention was monthly fremanezumab 225 mg in change from baseline of migraine days (standard mean difference = −0.49, 95% CI: −0.62, −0.37) and 50% response rate (risk ratio = 2.98, 95% CI: 2.16,4.10), while the optimal choice for reducing acute medication days was monthly erenumab 140 mg (standard mean difference = −0.68, 95% CI: −0.79, −0.58). In terms of AEs, all therapies and placebo did not achieve statistical significance except for monthly galcanezumab 240 mg and quarterly fremanezumab 675 mg. There was no significant difference in discontinuation due to AEs between interventions and placebo. Discussion: All anti-CGRP agents were more effective than placebo in migraine prevention. Overall, monthly fremanezumab 225 mg, monthly erenumab 140 mg, and daily atogepant 60 mg were effective interventions with fewer side effects." @default.
• W4379508729 created "2023-06-07" @default.
• W4379508729 creator A5013279584 @default.
• W4379508729 creator A5018943750 @default.
• W4379508729 creator A5025632345 @default.
• W4379508729 creator A5035869703 @default.
• W4379508729 creator A5038798689 @default.
• W4379508729 creator A5046135731 @default.
• W4379508729 creator A5068088670 @default.
• W4379508729 date "2023-06-02" @default.
• W4379508729 modified "2023-10-17" @default.
• W4379508729 title "Comparative Efficacy and Safety of Five Anti-Calcitonin Gene-Related Peptide Agents for Migraine Prevention" @default.
• W4379508729 cites W1984988711 @default.
• W4379508729 cites W1995699180 @default.
• W4379508729 cites W2038399206 @default.
• W4379508729 cites W2048326181 @default.
• W4379508729 cites W2085595272 @default.
• W4379508729 cites W2111548432 @default.
• W4379508729 cites W2122836206 @default.
• W4379508729 cites W2129181629 @default.
• W4379508729 cites W2136324281 @default.
• W4379508729 cites W2137787323 @default.
• W4379508729 cites W2157733244 @default.
• W4379508729 cites W2268603990 @default.
• W4379508729 cites W2299903968 @default.
• W4379508729 cites W2550010320 @default.
• W4379508729 cites W2608751463 @default.
• W4379508729 cites W2757577445 @default.
• W4379508729 cites W2768357559 @default.
• W4379508729 cites W2770965214 @default.
• W4379508729 cites W2780526171 @default.
• W4379508729 cites W2788340920 @default.
• W4379508729 cites W2792811290 @default.
• W4379508729 cites W2801085490 @default.
• W4379508729 cites W2803715733 @default.
• W4379508729 cites W2805181790 @default.
• W4379508729 cites W2805937849 @default.
• W4379508729 cites W2890199430 @default.
• W4379508729 cites W2893863004 @default.
• W4379508729 cites W2895868360 @default.
• W4379508729 cites W2898072840 @default.
• W4379508729 cites W2899821434 @default.
• W4379508729 cites W2901687990 @default.
• W4379508729 cites W2955283194 @default.
• W4379508729 cites W2968435022 @default.
• W4379508729 cites W2980838981 @default.
• W4379508729 cites W2982242065 @default.
• W4379508729 cites W2990435582 @default.
• W4379508729 cites W3007053288 @default.
• W4379508729 cites W3013502865 @default.
• W4379508729 cites W3036957975 @default.
• W4379508729 cites W3050017463 @default.
• W4379508729 cites W3086189755 @default.
• W4379508729 cites W3096774706 @default.
• W4379508729 cites W3164254563 @default.
• W4379508729 cites W3176461052 @default.
• W4379508729 cites W3176839476 @default.
• W4379508729 cites W3193766373 @default.
• W4379508729 cites W3194456276 @default.
• W4379508729 cites W3204748829 @default.
• W4379508729 cites W3217023082 @default.
• W4379508729 cites W4210800132 @default.
• W4379508729 cites W4214697113 @default.
• W4379508729 cites W4224289003 @default.
• W4379508729 cites W4254363211 @default.
• W4379508729 cites W4282934967 @default.
• W4379508729 cites W46438429 @default.
• W4379508729 doi "https://doi.org/10.1097/ajp.0000000000001136" @default.
• W4379508729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37278480" @default.
• W4379508729 hasPublicationYear "2023" @default.
• W4379508729 type Work @default.
• W4379508729 citedByCount "0" @default.
• W4379508729 crossrefType "journal-article" @default.
• W4379508729 hasAuthorship W4379508729A5013279584 @default.
• W4379508729 hasAuthorship W4379508729A5018943750 @default.
• W4379508729 hasAuthorship W4379508729A5025632345 @default.
• W4379508729 hasAuthorship W4379508729A5035869703 @default.
• W4379508729 hasAuthorship W4379508729A5038798689 @default.
• W4379508729 hasAuthorship W4379508729A5046135731 @default.
• W4379508729 hasAuthorship W4379508729A5068088670 @default.
• W4379508729 hasConcept C118303440 @default.
• W4379508729 hasConcept C126322002 @default.
• W4379508729 hasConcept C142724271 @default.
• W4379508729 hasConcept C163170386 @default.
• W4379508729 hasConcept C168563851 @default.
• W4379508729 hasConcept C170493617 @default.
• W4379508729 hasConcept C197934379 @default.
• W4379508729 hasConcept C204787440 @default.
• W4379508729 hasConcept C27081682 @default.
• W4379508729 hasConcept C2776478404 @default.
• W4379508729 hasConcept C2778541695 @default.
• W4379508729 hasConcept C2779627488 @default.
• W4379508729 hasConcept C2910587157 @default.
• W4379508729 hasConcept C535046627 @default.
• W4379508729 hasConcept C71924100 @default.
• W4379508729 hasConcept C95190672 @default.
• W4379508729 hasConcept C98274493 @default.
• W4379508729 hasConceptScore W4379508729C118303440 @default.

• next